RENAAL

Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan

Paziente / Popolazione Intervento / Esposizione Confronto Esito

In 1,513 patients with type 2 diabetes and nephropathy, losartan reduced the composite of creatinine doubling, ESRD or death compared with placebo.

1513

Disegno

Double-blind RCT, median 3.4-year follow-up

Esito

Doubling of serum creatinine, ESRD or death

Rilevanza

Risultato16% relative risk reduction (p=0.02); ESRD alone reduced 28% (p=0.002).

Brenner BM, et al. N Engl J Med. 2001;345(12):861-869. 10.1056/NEJMoa011161

Discussione e critica

First registration of an ARB for diabetic nephropathy; underpins the KDIGO 1A recommendation for ARBs in T2DM with albuminuria.